High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia
暂无分享,去创建一个
P. Feugier | S. Leprêtre | B. Grosbois | C. Dumontet | X. Leleu | A. Delmer | K. Maloum | B. Cazin | M. Leporrier | B. Dreyfus | O. Tournilhac | B. Mahé | F. Maloisel | H. Eghbali | O. Guibon | J. Jaubert | P. Travade | M. Diviné | J. Benichou | B. Mahé | M. Diviné
[1] J. Byrd,et al. Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101. , 2007 .
[2] D. Catovsky,et al. The Combination of Fludarabine and Cyclophosphamide Has a Beneficial Effect on the Incidence of Hemolytic Anemia in Chronic Lymphocytic Leukemia. Results from the UK LRF CLL4 Trial. , 2007 .
[3] H. Kantarjian,et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors , 2007, British journal of haematology.
[4] M. Grever,et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Hallek,et al. Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy , 2007, British journal of haematology.
[6] M. Hallek,et al. Consolidation with Alemtuzumab Improves Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia (CLL) in First Remission - Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG). , 2006 .
[7] D. Catovsky,et al. The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial. , 2006 .
[8] R. Greil,et al. Purine antagonists for chronic lymphocytic leukaemia. , 2006, The Cochrane database of systematic reviews.
[9] F. Ricci,et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Caligiuri,et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Brittinger,et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.
[12] M. Hallek,et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] H. Döhner,et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) , 2004, Leukemia.
[14] J. Rossi,et al. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Baudet,et al. Novel flow‐cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia , 2002, British journal of haematology.
[16] D. Huhn,et al. The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas , 2002, Anti-cancer drugs.
[17] J. Byrd,et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.
[18] F. Bosch,et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Feugier,et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. , 2001, Blood.
[20] R. Larson,et al. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. Kantarjian,et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Oscier,et al. The bioavailability of oral fludarabine phosphate is unaffected by food. , 2001, The hematology journal : the official journal of the European Haematology Association.
[23] B. Cheson,et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[24] E. Montserrat,et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. , 1999, Blood.
[25] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[26] J. Binet,et al. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). , 1999, Hematology and cell therapy.
[27] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[28] E. Estey,et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. , 1993, Blood.
[29] J Benichou,et al. Application of the triangular test to phase II cancer clinical trials. , 1990, Statistics in medicine.